Sentences with phrase «human epidermal growth factor receptor»

Others respond to another protein called human epidermal growth factor receptor 2, or HER2.

For years researchers have been developing molecular imaging techniques that visualize hormonally active breast cancer cells — specifically those testing positive for human epidermal growth factor receptor 2 (HER2).

An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

Some breast cancers have higher levels of a protein that promotes cancer growth called human epidermal growth factor receptor 2 (HER2).

The growth factors are human epidermal growth factor receptor 2 (HER2), human epidermal growth factor receptor 3 (HER3), and epidermal growth factor receptor (EGFR).

The study, called the PALOMA - 3, enrolled 521 pre - / peri - and postmenopausal patients with hormone receptor positive and human epidermal growth factor receptor - negative (HR + / HER2 --RRB- advanced disease.

Human epidermal growth factor receptor 2 (HER2) is upregulated in a subset of human breast cancers.

The analysis also found that Asian / Pacific Islander women were more likely to be diagnosed with another subtype of breast cancer: so - called human epidermal growth factor receptor 2 (HER2)- overexpressing breast cancer.

He examines several well - studied receptors — the bacterial aspartate receptor (Tar), human epidermal growth factor receptor (EGFR), and human brain - derived neurotrophin receptor (BDNFR)-- and comes to a conclusion that they all have similar chemical structures with or without their corresponding ligands.

Ince and his team found that although TNBC lacks the three receptors that fuel most breast cancers — estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 — it does express androgen receptors (AR) and vitamin D receptors (VDR).

Our lead product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from our Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer.

PALLAS: Palbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR +) / Human Epidermal Growth Factor Receptor 2 (HER2)- Negative Early Breast Cancer

Mucosal melanomas with mutations in CDK4 may respond to palbociclib or ribociclib, which have demonstrated activity in advanced hormone receptor — positive, human epidermal growth factor receptor 2 — negative breast cancer.

Chemotherapy is a key part of the standard treatment regimen for triple - negative breast cancer patients whose cancer lacks expression of estrogen and progesterone receptors and the human epidermal growth factor receptor 2...

The human epidermal growth factor receptor - 2 (HER2) gene makes proteins responsible for maintaining healthy cell growth, division and repair of breast tissue.

The subtype defined as triple negative breast cancer (TNBC) is negative for estrogen receptor, progesterone receptor, and the human epidermal growth factor receptor 2 (Her2).

[6] Breast cancers after Hodgkin lymphoma were enriched for the basal and human epidermal growth factor receptor 2 (HER2)- enriched tumor subtypes (50 % overall) and were found to have significantly higher expression of the Ki - 67 proliferation marker compared with controls, as well as a profile of chromosomal instability.

Many women are «triple negative» No one yet knows precisely why, but African - American women are roughly twice as likely as white women to have triple - negative breast cancer — so called because tumor cells in this particularly aggressive form of the disease test negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER - 2).

Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 in adjacent nonneoplastic mammary tissue were evaluated by immunohistochemistry.

In highly proliferative lesions with increased Ki67, estrogen receptor was negative, but human epidermal growth factor receptor 2 was usually positive with a distribution that was similar to that reported for human intraepithelial lesions (7).